Zepbound’s greater weight loss is a huge advantage for Eli Lilly, which is competing with Novo Nordisk for a larger share of the weight loss drug market.
Related Posts
Bank of Japan keeps rates steady as Trump tariffs cast a shadow over economic outlook
The BOJ’s decision comes ahead of the Federal Reserve’s policy meeting, where the U.S. central bank is expected to keep its benchmark interest rate steady.
UnitedHealth Group shares plunge 18% on reported DOJ probe into possible Medicare fraud
Shares of UnitedHealth Group are down roughly 49% this year following a string of setbacks for the company.
Needham upgrades Robinhood to buy, says Trump victory will boost the stock
This financial services platform is slated for more gains under a second Trump term, according to Needham.